*ST赛隆 (002898)
Sailong Pharmaceutical Group Co., Ltd.
K-Line Chart
No K-line data available
Company NameSailong Pharmaceutical Group Co., Ltd.
Listing Date2017-09-12
Issue Price8.31RMB
Registered Capital1760010k RMB
Legal RepresentativeChen Ke
Registered AddressUnit 2, 21st Floor, No. 31 Nanwan North Road, Xiangzhou District, Zhuhai City, Guangdong Province
IndustryChemical Pharmaceuticals
Main BusinessThe company is a pharmaceutical enterprise with GSP (Sailong Pharmaceutical) and GMP (Yueyang Sailong) certification qualifications. Its products are currently mainly concentrated in the fields of the nervous system, cardiovascular and cerebrovascular systems, and the digestive system. The main products operated include: Monosialotetrahexosylganglioside Sodium Active Pharmaceutical Ingredient (produced by Yueyang Sailong) and Injection (produced by Southwest Pharmaceutical), Cerebroprotein Hydrolysate for Injection (produced by Shanxi Pude), Clindamycin Phosphate for Injection, Pantoprazole Sodium for Injection, and Milrinone Injection, etc.
Company ProfileSailong Pharmaceutical Group Co., Ltd. was established in 2002. With the concept and speed of 'leapfrog' development, it entered the view of the industry and the public, achieving an annual growth rate exceeding 30%, and has become a high-quality pharmaceutical enterprise integrating drug research and development, production, sales, and technical services. It wholly owns two subsidiaries, Hunan Sailong Pharmaceutical Co., Ltd. and Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., and has a branch, Zhuhai Sailong Pharmaceutical Co., Ltd. (Changsha) Pharmaceutical R&D Center.
Stock Details
1. Key Indicators
- Total Shares(W): 17600.00
- Circulating A-Shares(W): 10126.26
- Earnings Per Share(RMB): -0.2295
- Net Assets Per Share(RMB): 2.6163
- Operating Revenue(W RMB): 20002.15
- Total Profit(W RMB): -3880.24
- Net Profit Attributable to Parent(W RMB): -4039.81
- Net Profit Growth Rate(%): -993.92
- Weighted Return on Equity(%): -8.4300
- Operating Cash Flow Per Share(RMB): -0.2090
- Undistributed Profit Per Share(RMB): -0.1344
- Capital Reserve Per Share(RMB): 1.6390
2. Main Business
The main business covers:
- Research, development, production, marketing and technical services of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations.
3. Company Basic Information
- Company Name: Sailong Pharmaceutical Group Co., Ltd.
- Listing Date: 2017-09-12
- Industry: Pharmaceutical Manufacturing
- Address: 21/F, Unit 2, No. 31 Nanwan North Road, Xiangzhou District, Zhuhai City, Guangdong Province, China
- Website: www.sailong.cn
- Company Profile: The issuer was restructured from Zhuhai Sailong Pharmaceutical Co., Ltd. based on its audited net asset value of RMB 37,790,370.97 as of September 30, 2014. After deducting RMB 15,000,000 for cash dividends, the remaining net assets of RMB 22,790,370.97 were converted into shares to establish Zhuhai Sailong Pharmaceutical Co., Ltd. as a joint-stock company, with 5 million shares issued and the remaining RMB 17,790,370.97 recorded as capital reserve. The shareholding ratios of all promoters remained unchanged before and after the restructuring. On December 11, 2014, Grant Thornton Certified Public Accountants (Special General Partnership) conducted the capital verification for the establishment of the joint-stock company and issued the Grant Thornton Capital Verification Report (Grant Thornton Capital Verification No. (2014) 110ZA0362). On December 22, 2014, the company obtained the Business License of Legal Person (Registration No. 440400000086623) from the Zhuhai Administration for Industry and Commerce.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hainan Yayi Win-Win Technology Partnership (Limited Partnership) | General Legal Person | 2491.22 | 24.60 |
| 2 | Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd. | General Legal Person | 1275.63 | 12.60 |
| 3 | MERRILL LYNCH INTERNATIONAL | QFII | 66.39 | 0.66 |
5. Concept Sectors
- ST Sector
- Helicobacter Pylori
- East Data West Computing
- Hepatitis Concept
- Innovative Drug
- Control Change
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information